BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 25255406)

  • 1. Target-specific oral anticoagulants: practice issues for the clinician.
    Plitt A; Giugliano RP
    Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Improvements in oral anticoagulant therapy for atrial fibrillation].
    Briongos Figuero S; García Santos-Gallego C; Badimón JJ
    Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching between oral anticoagulants.
    Strasser KM; Qasem A; Madhusudhana S
    Hosp Pract (1995); 2014 Aug; 42(3):68-74. PubMed ID: 25255408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
    Truffa AA; Lopes RD; Newby LK
    Postgrad Med; 2013 Mar; 125(2):146-57. PubMed ID: 23816780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
    Gonzalez-Quesada CJ; Giugliano RP
    Am J Cardiovasc Drugs; 2014 Apr; 14(2):111-27. PubMed ID: 24504768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral anticoagulants in elderly patients.
    Barco S; Cheung YW; Eikelboom JW; Coppens M
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thromboembolic prophylaxis 2011: is warfarin on the wane?].
    Di Pasquale G; Riva L
    G Ital Cardiol (Rome); 2011 Sep; 12(9):556-65. PubMed ID: 21892216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anticoagulants for stroke prevention in atrial fibrillation.
    Senoo K; Lane DA; Lip GY
    Curr Probl Cardiol; 2014 Sep; 39(9):319-44. PubMed ID: 25194766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
    Turagam MK; Velagapudi P; Bongu NR; Kocheril AG
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):79-86. PubMed ID: 25088126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
    Ezekowitz MD; Kent AP
    Circulation; 2014 Oct; 130(17):1505-14. PubMed ID: 25332278
    [No Abstract]   [Full Text] [Related]  

  • 18. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.